Global Vulvodynia Treatment Market, By Drug Class (Local Anesthetics, Antidepressants, Anticonvulsants, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Vulvodynia Treatment Market Analysis and Size
The global vulvodynia treatment market is expected to witness significant growth during the forecast period. The complex etiology of the disease and the symptoms associated with the comorbid pain conditions make the management difficult. Physiology, beliefs, emotions, experiences, lifestyles, and relationships all have a role in sexual response. Any component that is disturbed can have an impact on sexual and reproductive health. Developing markets and huge investment in research and development are the factors responsible for the growth of this market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global vulvodynia treatment market in the forecast period 2022-2029. The expected CAGR of global vulvodynia treatment market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 5.5 billion in 2021, and it would grow upto USD 9.10 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Vulvodynia is also known as vulvar pain, which is a reproductive disorder characterized by burning sensation, discomfort and chronic pain in the vulva. It may be triggered by touch. It is caused mainly by hypersensitivity to yeast infections or allergies or irritation to specific chemical agents.
Vulvodynia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Local Anesthetics, Antidepressants, Anticonvulsants, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland.), Pfizer Inc (U.S.), Lupin (India), Vintage Labs (India), Abbvie Inc. (U.S.), Zydus Group (India), Taro Pharmaceutical Industries Ltd (U.S.)
|
|
Market Opportunities
|
|
Global Vulvodynia Treatment Market Dynamics
Drivers
- Anaesthetic Gels & Creams and Appropriate Diet Options
The focus on multidisciplinary approaches for disease management leaves a positive impact on market prospects. A major trend boosting the vulvodynia demand growth is the increased acceptability of local anaesthetics in the form of gels or creams to decrease pain-related discomfort in the patient population. There is an increasing demand for lidocaine gel or cream. Improved research on first-line vulvodynia treatment is also driving the market's steady growth. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Awareness About the Sexual Dysfunction
Female sexual dysfunction has become a major problem globally, and this can strike at any age. Female sexual dysfunction treatment performed under a specialist's guidance can help overcome pain. Increased education and information on sexual health is also helping in rising awareness of female sexual dysfunction treatment across regions.
- Increasing Demand for Retail Pharmacies
Rise in the number of therapeutics related to vulvodynia being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of healthcare personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global vulvodynia treatment market over a forecast period.
- High Cost
The huge expenditure associated with vulvodynia medications surely hamper the market growth.
This global vulvodynia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vulvodynia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Vulvodynia Treatment Market
Over the period of 2020 and 2021, the COVID-19 pandemic had a major impact on most of the medical procedures. People were restricted from visiting hospitals for numerous medical treatments and procedures because of COVID-19 pandemic restrictions. The vulvodynia treatment market also saw a decline in demand, as the focus was mainly on COVID-19. Furthermore, there was a shortage of the equipment, drugs, and materials that was required to for the completion of successful vulvodynia treatment procedures. However, the global vulvodynia treatment market is again regaining its growth with the upliftment of everything and also the shift towards different other diseases.
Global Vulvodynia Treatment Market Scope
The global vulvodynia treatment market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Local Anesthetics
- Antidepressants
- Anticonvulsants
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Vulvodynia Treatment Market Regional Analysis/Insights
The global vulvodynia treatment market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global vulvodynia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for global vulvodynia treatment market throughout the forecasted period due to the rise of genitourinary diseases and an increase in awareness about the vulvodynia treatment and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase government initiatives and developing healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Vulvodynia Treatment Market Share Analysis
The global vulvodynia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vulvodynia treatment market
Key players operating in the global vulvodynia treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland.)
- Pfizer Inc (U.S.)
- Lupin (India)
- Vintage Labs (India
- Abbvie Inc. (U.S.)
- Zydus Group (India)
- Taro Pharmaceutical Industries Ltd (U.S.)
SKU-